Home/Pipeline/Tedopi® (OSE-2101)

Tedopi® (OSE-2101)

Non-Small Cell Lung Cancer (NSCLC)

Phase 3Active - Pivotal (ARTEMIA Trial)

Key Facts

Indication

Non-Small Cell Lung Cancer (NSCLC)

Phase

Phase 3

Status

Active - Pivotal (ARTEMIA Trial)

Company

OSE Immunotherapeutics

About OSE Immunotherapeutics

OSE Immunotherapeutics is an integrated, clinical-stage biotechnology company focused on developing first-in-class immunotherapies for immuno-oncology and immuno-inflammation. Its core strategy is driven by three proprietary technology platforms designed to precisely modulate the immune system. The company's most significant near-term catalyst is the Phase 3 ARTEMIA trial for Tedopi® in non-small cell lung cancer, which has received two positive IDMC recommendations. OSE aims to build value through a diversified pipeline and strategic partnerships.

View full company profile

Therapeutic Areas

Oncology Autoimmune Diseases Inflammation

Other Non-Small Cell Lung Cancer (NSCLC) Drugs

Drug	Company	Phase	Status
LW-02 Immunopheresis	Immunicom	Phase 2	Active
Idylla EGFR Mutation Assay	Biocartis	Approved	CE-IVD
ABD-3001	Advanced Biodesign	Phase 1	Active
Macrocyclic OMNI-EGFR Inhibitor	BlossomHill Therapeutics	Phase 1	Active
TUMORIN Clinical Trial	Nilogen Oncosystems	N/A (Diagnostic Validation)	Active
Membrex™	Metaclipse Therapeutics	Pre-clinical	Active
Lazertinib (Leclaza)	Genosco	Approved	Active
IPH5201 (anti-CD39 mAb)	Orega Biotech	Phase 2	Active
Platin-DRP®	Chosa Oncology	Validation	Active
Undisclosed RNA Immunotherapy	Epitopea	Pre-clinical	Active
Aspyre Clinical Test for Lung	Biofidelity	Commercial	Active
EGFR Mutation Detection Assay	Stilla Technologies	Assay Development/Validation	Active